CEPP

CEPP is an acronym for the name of a chemotherapy regimen that is intended for treatment of aggressive non-Hodgkin lymphomas. Unlike CHOP, this chemotherapy regimen does not contain doxorubicin or any other anthracycline. Thus, it can be used in patients with severe cardiovascular diseases and contraindications for doxorubicin-containing regimens. There are 2 modifications of CEPP - with the addition of bleomycin, called CEPP (B), and without bleomycin - ordinary CEPP.[1]

This regimen also does not contain vincristine and can be used in patients with neuropathy.

In combination with anti-CD20, monoclonal, antibody, and rituximab. this regimen is called R-CEPP(B).

[R]-CEPP(B) regimen consists of:

  1. (R)ituximab - a monoclonal antibody that is able to kill CD20-positive B cells, either normal or malignant;
  2. (C)yclophosphamide - an alkylating antineoplastic agent;
  3. (E)toposide - a topoisomerase inhibitor from the epipodophyllotoxin group;
  4. (P)rocarbazine - an alkylating antineoplastic agent;
  5. (P)rednisone or (P)rednisolone - a glucocorticoid hormone that has the ability to cause apoptosis and lysis of lymphocytes, either normal or malignant;
  6. (B)leomycin - an antitumor antibiotic.

Dosing regimen
DrugDoseModeDays
(R)ituximab375 mg/m2IV infusionDay 1
(C)yclophosphamide600 mg/m2IV infusionDays 1 and 8
(E)toposide70 mg/m2IV infusionDays 1-3
(P)rocarbazine60 mg/m2PO qdDays 1-10
(P)rednisone or (P)rednisolone60 mg/m2PO qdDays 1-10
(B)leomycin10 IU/m2IV bolusDay 1

References
  1. CEPP (B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.